-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to a recent announcement by Abbisko, the company will be officially listed on the Hong Kong Stock Exchange today (October 13)
Screenshot source: reference [2]
Heyu Medicine was established in 2016, the founder and CEO is Dr.
The company has established a pipeline of 14 drug candidates focused on oncology, including 5 drug candidates in the clinical stage
According to the prospectus, the net proceeds from Heyu Pharmaceutical's IPO will be used for the following purposes:
About 19.
Core candidate product ABSK011
About 32.
Core candidate product ABSK091 (AZD4547)
About 28.
Approximately 8.
Heyu Pharmaceutical Product Pipeline (Source of screenshots: Reference [3])
Possess a series of FGFR pipeline combinations
Possess a series of FGFR pipeline combinationsAccording to the prospectus, Heyu Medicine has a series of fibroblast growth factor receptor (FGFR) pipeline portfolio, covering multiple types of wild-type and mutant FGFR isoforms
Pan-FGFR inhibitors targeting specific FGFR subtypes of FGFR inhibitors A new generation of FGFR inhibitors
ABSK011 : Highly selective FGFR4 small molecule oral inhibitor developed by Heyu Medicine , which can inhibit the growth of tumors by inhibiting the activity of FGFR4 and blocking related signal transduction
ABSK011 Highly Selective FGFR4 Small Molecule Oral Inhibitor
ABSK091 (AZD4547) : A selective inhibitor of FGFR subtypes 1, 2 and 3.
ABSK091 (AZD4547) A selective inhibitor of FGFR subtypes 1, 2 and 3.
Other clinical stage drug candidates
In addition to FGFR candidate drugs, Heyu Medicine also formed a small molecule tumor immunotherapy candidate drug combination, targeting the main tumor microenvironmental immune cell types, including tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSC) , Treg cells, Th17/Tc17 cells and effector T cells
Image source: 123RF
ABSK021: A selective small molecule CSF-1R inhibitor , which is being developed for the treatment of various types of tumors and non-tumor indications
ABSK021: a selective small molecule CSF-1R inhibitor
ABSK081 (mavorixafor): an oral CXCR4 antagonist
ABSK081 (mavorixafor): an oral CXCR4 antagonist
ABSK043: A highly selective small molecule PD-L1 inhibitor , which is being developed to treat a variety of cancers and potential non-tumor indications
ABSK043: A highly selective small molecule PD-L1 inhibitor
references:
references:[1]02256-Heyu-B-New listing.
[1]02256-Heyu-B-New listing.
[2] Announcement of Offer Price and Allocation Results.
Retrieved Oct 11.
2021.
from hhttps://pdf.
dfcfw.
com/pdf/H2_AN202110121522101007_2.
pdf?1634027871000.
[3] Heyu Pharmaceutical Prospectus.
From https://www2.
hkexnews.
hk/New-Listings/New-Listing-Information/Main-Board?sc_lang=zh-HK
From https://www2.
hkexnews.
hk/New-Listings/New-Listing-Information/Main-Board?sc_lang=zh-HK